Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Importance: Antithrombotic therapy is crucial for older patients with coronary artery disease (CAD) and atrial fibrillation (AF) who are at a high risk of bleeding and thrombotic events. Objective: To examine the age-stratified effects of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet agent combination therapy. Design, Setting, and Participants: This was a post hoc secondary analysis of the Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease (AFIRE) open-label randomized clinical trial. This was a multicenter study conducted in Japan from February 23, 2015, to July 31, 2018. Patients with AF and stable CAD who had undergone percutaneous coronary intervention or coronary artery bypass grafting 1 or more years earlier or who had angiographically confirmed CAD that did not require revascularization were enrolled. Participants were stratified into 4 groups by age (<70 years, 70-74 years, 75-79 years, and ≥80 years). Study data were analyzed from August 2024 to July 2025. Interventions: Rivaroxaban monotherapy or rivaroxaban plus antiplatelet agent therapy. Main Outcomes and Measures: The primary efficacy end point was a major adverse cardiovascular event, defined as a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death from any cause. The primary safety end point was major bleeding. Results: This study included a total of 2215 participants (mean [SD] age, 74.3 [8.2] years; 1751 male [79.1%]). The incidence of primary efficacy end points per patient-year for rivaroxaban monotherapy vs rivaroxaban plus antiplatelet agent therapy was 3.2% vs 4.3% (<70 years), 3.2% vs 2.8% (70-74 years), 3.8% vs 5.3% (75-79 years), and 6.2% vs 10.3% (≥80 years). The hazard ratios were 0.74 (95% CI, 0.40-1.37) for those younger than 70 years, 1.16 (95% CI, 0.55-2.45) for those aged 70 to 74 years, 0.72 (95% CI, 0.41-1.26) for those aged 75 to 79 years, and 0.61 (95% CI, 0.40-0.93) for those 80 years and older (P for interaction =.51). For the primary safety end points, the incidence was 0.5% vs 2.3% (<70 years), 2.2% vs 2.4% (70-74 years), 1.1% vs 2.1% (75-79 years), and 2.9% vs 4.3% (≥80 years). The hazard ratios were 0.23 (95% CI, 0.06-0.79) for those younger than 70 years, 0.91 (95% CI, 0.39-2.15) for those aged 70 to 74 years, 0.52 (95% CI, 0.19-1.42) for those aged 75 to 79 years, and 0.67 (95% CI, 0.35-1.27) for those 80 years and older (P for interaction =.33). Conclusions and Relevance: Results of this post hoc analysis of the AFIRE randomized clinical trial reveal that rivaroxaban monotherapy reduced the risk of major cardiovascular events and major bleeding across the broad range of age in patients with AF and stable CAD. Possible age-related differences in trends, with more pronounced efficacy in older patients and more pronounced safety in younger patients, should be considered as hypothesis generating and require further research. Trial Registration: ClinicalTrials.gov Identifier: NCT02642419.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease
- Date Crossref
- 01/10/2025
- Éditeur
- American Medical Association (AMA)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tokyo Women's Medical University Department of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Tohoku University Department of Cardiovascular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
National Cerebral and Cardiovascular Center pays non établi dans la noticeÉtablissement de santé
-
University of Miyazaki pays non établi dans la noticeUniversité ou école supérieure
-
Kumamoto University Department of General Medicine and Primary Care pays non établi dans la noticeUniversité ou école supérieure
-
Kyoto Medical Center Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Kitasato University Department of Cardiovascular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Kyushu University pays non établi dans la noticeUniversité ou école supérieure
-
Toho University Division of Cardiovascular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Toho University Ohashi Medical Center pays non établi dans la noticeÉtablissement de santé
-
Tokyo Metropolitan Geriatric Hospital pays non établi dans la noticeÉtablissement de santé
-
Kumamoto University Hospital pays non établi dans la noticeÉtablissement de santé
Department of Cardiology — Tokyo Women's Medical University, Department of Cardiovascular Medicine — Tohoku University et National Cerebral and Cardiovascular Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.